These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
184 related articles for article (PubMed ID: 15323184)
1. The Maillard reaction inhibitors and their biological and therapeutic significance. Sztanke K; Pasternak K Ann Univ Mariae Curie Sklodowska Med; 2003; 58(2):156-8. PubMed ID: 15323184 [TBL] [Abstract][Full Text] [Related]
2. The Maillard reaction and its consequences for a living body. Sztanke K; Pasternak K Ann Univ Mariae Curie Sklodowska Med; 2003; 58(2):159-62. PubMed ID: 15323185 [TBL] [Abstract][Full Text] [Related]
3. Protein crosslinking by the Maillard reaction: dicarbonyl-derived imidazolium crosslinks in aging and diabetes. Chellan P; Nagaraj RH Arch Biochem Biophys; 1999 Aug; 368(1):98-104. PubMed ID: 10415116 [TBL] [Abstract][Full Text] [Related]
4. Pyrraline ether crosslinks as a basis for protein crosslinking by the advanced Maillard reaction in aging and diabetes. Nagaraj RH; Portero-Otin M; Monnier VM Arch Biochem Biophys; 1996 Jan; 325(2):152-8. PubMed ID: 8561492 [TBL] [Abstract][Full Text] [Related]
5. A quantitative model of the generation of N(epsilon)-(carboxymethyl)lysine in the Maillard reaction between collagen and glucose. Ferreira AE; Ponces Freire AM; Voit EO Biochem J; 2003 Nov; 376(Pt 1):109-21. PubMed ID: 12911334 [TBL] [Abstract][Full Text] [Related]
6. Maillard reaction products in tissue proteins: new products and new perspectives. Thorpe SR; Baynes JW Amino Acids; 2003 Dec; 25(3-4):275-81. PubMed ID: 14661090 [TBL] [Abstract][Full Text] [Related]
7. Inhibitors of the Maillard reaction and AGE breakers as therapeutics for multiple diseases. Reddy VP; Beyaz A Drug Discov Today; 2006 Jul; 11(13-14):646-54. PubMed ID: 16793534 [TBL] [Abstract][Full Text] [Related]
8. Glycoxidation: the menace of diabetes and aging. Vlassara H; Palace MR Mt Sinai J Med; 2003 Sep; 70(4):232-41. PubMed ID: 12968196 [TBL] [Abstract][Full Text] [Related]
9. Cross-linking of the extracellular matrix by the maillard reaction in aging and diabetes: an update on "a puzzle nearing resolution". Monnier VM; Mustata GT; Biemel KL; Reihl O; Lederer MO; Zhenyu D; Sell DR Ann N Y Acad Sci; 2005 Jun; 1043():533-44. PubMed ID: 16037276 [TBL] [Abstract][Full Text] [Related]
10. Toxicity of the AGEs generated from the Maillard reaction: on the relationship of food-AGEs and biological-AGEs. Chuyen NV Mol Nutr Food Res; 2006 Dec; 50(12):1140-9. PubMed ID: 17131455 [TBL] [Abstract][Full Text] [Related]
11. Toward a Maillard reaction theory of aging. Monnier VM Prog Clin Biol Res; 1989; 304():1-22. PubMed ID: 2675024 [TBL] [Abstract][Full Text] [Related]
12. The maillard reaction in eye diseases. Stitt AW Ann N Y Acad Sci; 2005 Jun; 1043():582-97. PubMed ID: 16037281 [TBL] [Abstract][Full Text] [Related]
13. The Maillard reaction in the human body. The main discoveries and factors that affect glycation. Tessier FJ Pathol Biol (Paris); 2010 Jun; 58(3):214-9. PubMed ID: 19896783 [TBL] [Abstract][Full Text] [Related]
14. Peptide and amino acid glycation: new insights into the Maillard reaction. Horvat S; Jakas A J Pept Sci; 2004 Mar; 10(3):119-37. PubMed ID: 15113085 [TBL] [Abstract][Full Text] [Related]
15. Fructose-mediated non-enzymatic glycation: sweet coupling or bad modification. Schalkwijk CG; Stehouwer CD; van Hinsbergh VW Diabetes Metab Res Rev; 2004; 20(5):369-82. PubMed ID: 15343583 [TBL] [Abstract][Full Text] [Related]
19. Pharmacological prevention of cardiovascular aging--targeting the Maillard reaction. Aronson D Br J Pharmacol; 2004 Aug; 142(7):1055-8. PubMed ID: 15237100 [TBL] [Abstract][Full Text] [Related]
20. Targeting advanced glycation with pharmaceutical agents: where are we now? Borg DJ; Forbes JM Glycoconj J; 2016 Aug; 33(4):653-70. PubMed ID: 27392438 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]